Three years ago I1 published a short report of progress on the use of ephedrine in a case of myasthenia gravis. The correspondence that has developed with physicians and relatives of patients having myasthenia gravis seems to make a further report desirable.
In the past three years, except for short periods when the ephedrine has been discontinued or the dose increased, for experimental purposes, I have taken a daily dose of 6/8 grain (48 mg.) of ephedrine sulphate or of ephedrine hydrochloride with slow but continuous improvement. The rate of improvement has been apparently uniform; that is, the amount of improvement during the last six months seems to have been as great as during the first six months. Larger doses give me a temporary increase in strength, but these dosages are invariably followed in two or three weeks by such adverse symptoms that I have always been compelled to
Edgeworth H. THE EFFECT OF EPHEDRINE IN THE TREATMENT OF MYASTHENIA GRAVIS: SECOND REPORT. JAMA. 1933;100(18):1401. doi:10.1001/jama.1933.27420180001007
Customize your JAMA Network experience by selecting one or more topics from the list below.